Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
In this retrolective, multicentric study, medical charts of RA patients starting TNFi
between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The
retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done
after adjustment using a Cox model. Factors associated with better retention were identified
by multivariate analysis. Medical charts of all patients with RA starting a first TNFα
inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France)
and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in
detail by 2 rheumatologist investigators
Observational
Time Perspective: Retrospective
Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA
2 years
No
Pfizer CT.gov Call Center
Study Director
Pfizer
France: The Commission nationale de l’informatique et des libertés
NRB1800007
NCT01692899
June 2011
September 2011
Name | Location |
---|